BOHAI PARMACEUTICALS GROUP, INC.

c/o Yantai Bohai Pharmaceuticals Group Co. Ltd.

No. 9 Daxin Road, Zhifu District

Yantai, Shandong Province, China 264000

August  10, 2010

VIA EDGAR TRANSMISSION

Mr. Jeffrey Riedler

Division of Corporation Finance

Mail Stop 4720

United States Securities and Exchange Commission

450 Fifth Street, N.W.

Washington, D.C. 20549

Re:	Bohai Pharmaceuticals Group, Inc.
	Registration Statement on Form S-1, as amended
	File No. 333-165149

Dear Mr. Riedler:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Bohai Pharmaceuticals Group, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. on Wednesday, August 11, 2010, or as soon as thereafter practicable.

Please note that we acknowledge the following:

·   should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·   the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

·   the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,

/s/ Gene Hsiao  

Gene Hsiao

Chief Financial Officer